Ca-AKG side effects and safety profile

Ca-AKG appears reasonably well tolerated in the human studies published so far, but the safety database is smaller and messier than “no side effects reported” makes it sound.

Direct human Ca-AKG exposure spans healthy volunteers, postmenopausal women, and several older dialysis cohorts. Most studies were small, some were conducted for non-longevity indications, and adverse-event reporting was not always modern or systematic.

This page separates what has actually been observed from what remains unknown. For dose-specific context, see Ca-AKG dosage. For the broader evidence, see the Ca-AKG evidence guide.

What side effects have actually been reported?

The clearest randomized Ca-AKG safety information comes from the 2007 osteopenia trial. Seventy-six postmenopausal women were randomized, and the Ca-AKG group received 6 g/day for 24 weeks. Overall dropout rates were the same between groups, but mild dyspepsia was more common in the Ca-AKG group — six cases versus one in the calcium-only group. The symptoms were generally transient and did not drive discontinuation [1].

An older randomized crossover study in people receiving chronic haemodialysis provides a less reassuring signal. Of 17 patients exposed to calcium ketoglutarate, five withdrew early because of gastrointestinal or general intolerance; several had pre-existing gastrointestinal symptoms [2].

Another dialysis crossover study involving 28 patients found calcium ketoglutarate broadly comparable with calcium acetate for phosphate control, with fewer episodes of hypercalcaemia in the calcium-ketoglutarate arm in that specific renal population [3].

So the evidence does not support saying “Ca-AKG causes no side effects.” A better summary is: serious toxicity has not emerged in the small human literature, while gastrointestinal intolerance has been reported and safety monitoring has varied substantially across studies.

How much human exposure data do we actually have?

The human Ca-AKG literature includes more than modern longevity supplementation.

Study	Population	Exposure	Safety relevance
Cynober 1990	6 healthy men	3.6 g single oral dose	Acute metabolic exposure; very small study
Riedel 1996	24 haemodialysis patients	Long-term Ca-AKG	One-year clinical exposure in a medically complex population
Zimmermann 1996	14 haemodialysis patients	Mean ~4.5 g/day	36 months of exposure; uncontrolled renal cohort
Bro 1998	19 enrolled haemodialysis patients	Randomized crossover	GI/general intolerance caused several early withdrawals
Birck 1999	28 haemodialysis patients	Two 12-week treatment periods	Mineral-metabolism and tolerability data
Filip 2007	76 postmenopausal women with osteopenia	6 g/day for 24 weeks	Randomized trial; mild dyspepsia signal

The acute healthy-volunteer study confirms oral Ca-AKG exposure is biologically active [4]. The one-year and three-year dialysis studies extend the duration of human exposure substantially beyond six months [5] [6].

These older studies are useful safety context, but they should not be treated as direct evidence that years of self-directed Ca-AKG use are safe in otherwise healthy adults. Dialysis changes calcium, phosphate and amino-acid metabolism in ways that do not generalize cleanly to a longevity-supplement population.

What about Rejuvant and ABLE?

The 2021 Rejuvant paper was a retrospective observational analysis, not a formal safety trial. It was not designed to establish an adverse-event rate for Ca-AKG [7].

The ABLE study is more important for future safety evidence because it is randomized and placebo-controlled. But the published ABLE protocol and recruitment paper contain no treatment safety outcomes yet [8] [9].

So it is incorrect to cite ABLE today as evidence that six months of Ca-AKG caused no adverse events. That result has not been published.

How much calcium is in Ca-AKG?

Ca-AKG is a calcium salt, so the supplement contributes to total calcium intake.

The exact elemental-calcium fraction depends on the chemical form, hydration state and how the manufacturer declares the ingredient. A rough rule is that calcium can make up about one-fifth of the salt mass, but the product's Supplement Facts should take priority over a generic conversion.

This matters more at higher Ca-AKG doses or when a person already takes calcium supplements.

The US NIH lists adult calcium tolerable upper intake levels of 2,500 mg/day for adults aged 19–50 and 2,000 mg/day for adults aged 51 and older. NIH calcium fact sheet.

Ca-AKG does not need to push someone near those limits to be relevant. The practical point is simply to count its calcium contribution rather than treating it as “AKG only.”

Can Ca-AKG cause kidney stones?

This has not been directly tested as a Ca-AKG outcome.

Kidney-stone risk depends on much more than total calcium intake, including dietary pattern, fluid intake, stone type, urinary chemistry and whether calcium comes from food or supplements. It is therefore too simplistic to say that the calcium in Ca-AKG “causes kidney stones.”

If you have recurrent stones, chronic kidney disease, abnormal calcium levels or a disorder of calcium metabolism, Ca-AKG is worth discussing with the clinician managing that condition before adding it to your regimen.

Does Ca-AKG interact with medications?

There is no comprehensive Ca-AKG-specific drug-interaction study.

The clearest interaction concern comes from the calcium component. Calcium supplements can interfere with absorption of medicines including levothyroxine and some quinolone antibiotics; tetracycline labeling also warns that calcium-containing products can impair absorption. The exact spacing depends on the medication. NIH calcium interaction guidance.

This is why the safer rule is not “separate Ca-AKG from every drug by four hours.” It is: check the label or ask a pharmacist about the specific medication.

See when to take Ca-AKG for the timing details.

Is Ca-AKG safe during pregnancy or breastfeeding?

There is no adequate direct safety evidence for supplemental Ca-AKG during pregnancy or breastfeeding.

That does not mean harm has been demonstrated. It means the relevant population has not been studied well enough to make a confident safety claim. If you are pregnant, trying to conceive or breastfeeding, discuss the supplement with your obstetric or primary-care clinician rather than extrapolating from studies in older adults.

What does animal toxicology show?

A dedicated 2011 repeated-dose toxicology study administered oral alpha-ketoglutarate to male and female Wistar rats for 14 days with a recovery period [10].

Animal toxicology is useful for detecting obvious hazards and target-organ signals, but it does not establish long-term human safety at supplement doses. The compound, species and exposure conditions also need to match before translating a toxicology margin directly.

Who should be more cautious?

Extra clinical review makes sense if you:

• have chronic kidney disease, recurrent kidney stones or known abnormal calcium metabolism;
• take medicines whose absorption is affected by calcium;
• take multiple calcium-containing supplements;
• are pregnant, trying to conceive or breastfeeding;
• are receiving active cancer treatment, where metabolic interventions should be discussed with the oncology team rather than added independently.

A family history of cancer alone is not a known Ca-AKG contraindication. The separate Ca-AKG and cancer article explains why AKG biology in cancer is context-dependent.

What are the biggest safety gaps?

Healthy-adult long-term use. The longest direct Ca-AKG exposure records come from small dialysis cohorts, not large healthy populations.

Systematic interaction testing. We mostly infer medication concerns from calcium pharmacology rather than Ca-AKG-specific interaction trials.

Pregnancy and breastfeeding. Direct evidence is lacking.

Formulation-specific safety. Immediate-release, sustained-release and combination products should not automatically be assumed to have identical tolerability.

Modern adverse-event surveillance. Several of the longest human exposure studies are older and were not designed with today's supplement-safety reporting standards.

Bottom line

Ca-AKG has a reasonably reassuring human exposure history, but “no safety signal” is too absolute.

Published human studies include mild dyspepsia and gastrointestinal/general intolerance in some participants, while serious toxicity has not emerged as a consistent pattern. Human exposure extends beyond six months in older dialysis studies, but those populations do not answer the long-term healthy-longevity safety question.

The practical safety issues are the calcium contribution, medication-specific calcium interactions, kidney/mineral-metabolism context, and the lack of pregnancy or long-term healthy-adult data.

For the complete evidence picture, return to the Ca-AKG pillar guide.